Novel Immunosuppression: Small Molecules and Biologics

Seminars in Nephrology

Volumn 27, Issue 4, 2007, Pages 479-486

  Yabu, Julie M ^a   Vincenti, Flavio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

costimulation; Immunosuppression; kidney transplantation; monoclonal antibodies

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; AEB 071; ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; EVEROLIMUS; FINGOLIMOD; HU5C8; JANUS KINASE 3 INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PROTEIN KINASE INHIBITOR; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; GRAFT SURVIVAL; HEART DISEASE; HUMAN; HYPOKALEMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG DISEASE; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA EDEMA; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TREATMENT OUTCOME;

EID: 34347237615     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.03.009     Document Type: Article

References (39)

1. Kunzendorf U., Ziegler E., and Kabelitz D. FTY720-the first compound of a new promising class of immunosuppressive drugs. Nephrol Dial Transplant 19 (2004) 1677-1682
2. Matloubian M., Lo C.G., Cinamon G., et al. Lymphocyte egress from the thymus and peripheral lymphocyte organs is dependent on S1P receptor 1. Nature 427 (2004) 355-360
3. Tedesco-Silva H., Mourad G., Kahan B.D., et al. FTY720, a novel immunomodulatory: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 79 (2005) 1553-1560
4. Mulgaonkar S., Tedesco H., Oppenheimer F., et al. FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study. Am J Transplant 6 (2006) 1848-1857
5. Pescovitz M., and FTY 720 0125 Study Group. A one year randomized controlled efficacy and safety trial of FTY720, versus mycophenolate mofetil with cyclosporine and corticosteroids in de novo renal transplantation. [abstract]. Am J Transplant 6 (2006) 84
6. Salvadori M., Budde K., Charpentier B., et al. FTY720 a novel immunomodulatory, vs. mycophenolate mofetil with cyclosporine microemulsion in de novo renal transplantation, a one-year randomized controlled trial in 668 patients from Europe and Australia. [abstract]. Am J Transplant 6 (2006) 346
7. Kappos L., Antel J., and Comi G. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355 (2006) 1124-1140
8. Savikko J., Von Willebarnd E., Hayry P., et al. Leflunamide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restonosis and chronic rejection. Transplantation 76 (2003) 455-458
9. Birsan T., Dambrin C., Klupp J., et al. Effects of the malononitrialamide FK778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers. Transpl Immunol 11 (2003) 163-167
10. Vanenterghem Y., Van Hooff J.P., Klinger M., et al. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation 78 (2004) 9-14
11. Podder H., and Kahan B.D. Janus kinase 3: a novel target for selective transplant immunosuppression. Expert Opin Ther Targets 8 (2004) 613-629
12. Saemann M.D., Zeyda M., Stulnig T.M., et al. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transpl Int 17 (2004) 481-489
13. Li X.C., Ima A., Li Y., et al. Blocking the common gamma-chain of cytokine receptors induces T cell apoptosis and long-term islet allograft survival. J Immunol 164 (2000) 1193-1199
14. Papageorgiou A.C., and Wikman L.E. Is JAK3 a new drug target for immunomodulation-based therapies?. Trends Pharmacol Sci 25 (2004) 558-562
15. Borie D.C., Changelian P.S., Larson M.J., et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 79 (2005) 791-801
16. Borie D.C., Larson M.J., Flores M.G., et al. JAK3 inhibitor, CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation 80 (2005) 1756-1764
17. Tan S.L., and Parker P.J. Emerging and diverse roles of protein kinase C in immune cell signaling. Biochem J 376 (2003) 545-552
18. Evenou J.P., Brinkmann V., Towbin H., et al. Enzymatic and cellular characterization of NVO-AEB0871, a novel and selective protein kinase C (PKC) inhibitor that blocks early T cell activation, and its use to define the role of PKC in T cells. [abstract]. Am J Transplant 6 (2006) 1026
19. Evenou J.P., Thuille N., Cottens R., et al. NVP-AEB071, a novel protein kinase C inhibitor, abrogates early mouse T cell activation without affecting activation induced cell death. [abstract]. Am J Transplant 6 (2006) 1029
20. Slade A.V., Agyemang A., Siberling M., et al. NVP-AEB071: human pharmacodynamics in combination with mycophenolic acid. [abstract]. Am J Transplant 6 (2006) 199
21. Slade A., Hijazi Y., Wagner J., et al. NVP-AEB071: pharmacokinetics and pharmacodynamic activity of a novel T-cell activation inhibitor under multiple-dose conditions. [abstract]. Am J Transplant 6 (2006) 198
22. Wagner T., Evenou J.-P., Zenke G., et al. The first-in-class oral protein kinase C (PKD) inhibitor NVP-AEB071 (AEB) prolongs renal allograft survival in non-human primates and suppresses lymphocyte proliferation at safe exposures in human proof-of-concept studies. [abstract]. Am J Transplant 6 (2006) 86
23. Bigaud M., Wierczorek G., Riesen S., et al. NVP-AEB071 (AEB), a novel oral inhibitor of early T-cell activation, prolongs the survival of non-human primate kidney allografts when used as monotherapy or at non-effective doses combined with a non-effective dose of cyclosporine. [abstract]. Am J Transplant 6 (2006) 250
24. Biguad M., Wierczorek G., Preussing E., et al. The novel oral inhibitor of protein kinase C and early T-cell activation prolongs non-human primates kidney allograft survival when combined with everolimus, ERL080 or FTY720 without calcineurin inhibitor. [abstract]. Am J Transplant 6 (2006) 251
25. Vincenti F. Induction therapy in kidney transplantation. In: Pereira B.J.G., Sayegh M.H., and Blake P. (Eds). Chronic kidney disease, dialysis, and transplantation: companion to Brenner & Rector's the kidney (2005), Elsevier Saunders, Philadelphia, PA 647-652
26. Krensky A.M., Vincenti F., and Bennett W. Immunomodulators: immunosuppressive agents, tolerogens and immunostimulants. In: Brunton L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's the pharmacologic basis of therapeutics. 11th ed. (2006), McGraw-Hill, New York, NY 1405-1432
27. Vincenti F. Chronic induction: what's new in the pipeline. In: Ronco C., Chiaramonte S., and Remuzzi G. (Eds). Kidney transplantation: strategies to prevent organ rejection (2005), Krager, Switzerland 22-29
28. Vincenti F. What's in the pipeline?. New immunosuppressive drugs in transplantation. Am J Transplant 2 (2002) 898-903
29. Kim S.Y., Maslinski W., Zheng X.X., et al. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fcg2a protein blocks delayed-type hypersensitivity. J Immunol 160 (1998) 5742-5748
30. Vincenti F., Mendez R., Rajogopalan P.R., et al. A phase I/II trial of anti-CD11a monoclonal antibody in renal transplantation. [abstract]. Am J Transplant 1 Suppl (2001) 276
31. Waldman T., Tagaya Y., and Bamford R. Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol 16 (1998) 205
32. Zheng X.X., Sanchez-Fueyo A., Masayuki S., et al. Favorable tipping the balance between cytopathic and regulatory cells to create transplantation tolerance. Immunity 19 (2003) 503-514
33. Pavlakis M., Strehlau J., Lipman M., et al. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 62 (1996) 543-545
34. Kirk A.D., Burkly L.C., Batty D.S., et al. Humanized anti-CD154 monoclonal antibody treatment prevents acute renal allograft rejection in non-human primates. Nat Med 5 (1999) 686-693
35. Kirk A.D., Knechtle S.J., Sollinger H.W., et al. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation. [abstract]. Am J Transplant 1 Suppl 1 (2001) 190
36. Andre P., Prasad K.S., Denis C.V., et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 8 (2002) 247-252
37. Sayegh M.H., and Turka L.A. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 338 (1998) 1813-1821
38. Larsen C.P., Pearson T.C., Adams A.B., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5 (2005) 443-453
39. Vincenti F., Larsen C., Durrbach A., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353 (2005) 770-781